According to a real-world study, cenobamate was effective in patients with drug-resistant epilepsy (DRE), with 49.3% of patients achieved a 50% or greater reduction in seizure frequency at 3 months.

The cost-effectiveness agency has backed Ontozry (cenobamate) as an option for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy ...

SEOUL, Jan. 15 (Yonhap) -- SK Biopharmaceuticals Co. (SK Biopharm), a biopharmaceutical arm of SK Group, will establish a joint venture with a major South American biopharma, Eurofarma, in the ...

This presentation reinforces the growing body of clinical and real-world evidence supporting cenobamate's role in reducing seizure activity and optimizing epilepsy management. "Our goal at SK Life ...

That list now includes an approval from the US FDA, which cleared SK Biopharmaceuticals’ anti-epileptic drug cenobamate in 2019. The approval further validated Korean science and KDDF’s model ...

The company recently received regulatory approval to conduct Phase III clinical trials for Cenobamate, an advanced anti-seizure medication. It has also secured key international contracts ...